|
MechanismHSP90B1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
注射用KMHH-03在晚期乳腺癌受试者中的安全性、耐受性及药代动力学特征研究
[Translation] Study on the safety, tolerability and pharmacokinetic characteristics of KMHH-03 for injection in subjects with advanced breast cancer
主要目的:
(1) 评价注射用KMHH-03在晚期乳腺癌受试者中的安全性及耐受性;
(2) 确定注射用KMHH-03单次给药的剂量限制性毒性(DLT)与最大耐受剂量(MTD)。
次要目的:
(1) 评价注射用KMHH-03在晚期乳腺癌受试者中的药代动力学(PK)特征;
(2) 评估注射用KMHH-03在晚期乳腺癌受试者中的免疫原性;
(3) 观察注射用KMHH-03在晚期乳腺癌受试者中的初步疗效,为后续临床试验推荐剂量和给药方案提供依据。
[Translation] Primary objectives:
(1) To evaluate the safety and tolerability of KMHH-03 for injection in subjects with advanced breast cancer;
(2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of a single dose of KMHH-03 for injection.
Secondary objectives:
(1) To evaluate the pharmacokinetic (PK) characteristics of KMHH-03 for injection in subjects with advanced breast cancer;
(2) To evaluate the immunogenicity of KMHH-03 for injection in subjects with advanced breast cancer;
(3) To observe the preliminary efficacy of KMHH-03 for injection in subjects with advanced breast cancer and provide a basis for the recommended dose and dosing regimen for subsequent clinical trials.
100 Clinical Results associated with Beijing Kangming Hanghui Biotechnology Co Ltd.
0 Patents (Medical) associated with Beijing Kangming Hanghui Biotechnology Co Ltd.
100 Deals associated with Beijing Kangming Hanghui Biotechnology Co Ltd.
100 Translational Medicine associated with Beijing Kangming Hanghui Biotechnology Co Ltd.